UBS Maintains Buy on Acumen Pharmaceuticals, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Colin Bristow maintains a Buy rating on Acumen Pharmaceuticals (NASDAQ:ABOS) but lowers the price target from $14 to $6.

August 15, 2024 | 1:11 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
UBS analyst Colin Bristow maintains a Buy rating on Acumen Pharmaceuticals but lowers the price target from $14 to $6.
The Buy rating suggests continued confidence in the company's long-term prospects, but the significant reduction in the price target indicates concerns about short-term performance or valuation. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100